...
首页> 外文期刊>Global heart >Very Early Versus Early Percutaneous Coronary Intervention After Successful Fibrinolytic Therapy in Pharmacoinvasive Strategy
【24h】

Very Early Versus Early Percutaneous Coronary Intervention After Successful Fibrinolytic Therapy in Pharmacoinvasive Strategy

机译:早期与药物侵袭策略成功纤维蛋白溶解治疗后的早期经皮冠状动脉干预

获取原文
获取原文并翻译 | 示例
           

摘要

BackgroundThe proper time for the use of percutaneous coronary intervention (PCI) following the successful fibrinolysis for ST-segment elevation myocardial infarction (STEMI) for maximum efficiency and minimum side effects has not been determined yet. The present study was designed to compare the outcome of myocardial infarction patients who received fibrinolytic therapy with successful results and underwent PCI very early (within 3–12 h) (group 1) versus early (within 12–24 h) (group 2). MethodsThe study compared the occurrence of major adverse cardiac events during PCI (no-reflow phenomenon, access site bleeding, cerebral hemorrhage, and cardiac death). Patients were followed for 6 months after PCI for the occurrence of unstable angina, recurrent angina, non-STEMI, recurrent STEMI, repeat revascularization, heart failure, and cardiac death. ResultsGroup 1 (121 patients) with the mean age of 59.93 ± 10.43 years were compared with group 2 (144 patients) with the mean age of 62.84 ± 10.22 years. Except for age, the 2 groups were not significantly different regarding baseline characteristics. No-reflow phenomenon was less in group 1 with p value?= 0.005, whereas incidence of access site bleeding and cerebral hemorrhage were more in this group with p value?= 0.001 and 0.049, respectively. During the period of 6 months' follow-up, recurrent angina and recurrent non-STEMI occurred more in group 2 with p value?= 0.049 and 0.035, respectively, with no other significant difference between the 2 groups. ConclusionsNo-reflow phenomenon and the risk of recurrent ischemia is significantly lower in patients undergoing PCI very early after successful fibrinolytic therapy, but the risk of bleeding is increased in this time. So it is recommended that patients received successful fibrinolytic therapy to be subjected to very early PCI within 3 to 12 h from fibrinolysis.
机译:背景技术在成功纤维蛋白溶解中使用经皮冠状动脉干预(PCI)的适当时间尚未确定最大效率和最小副作用的ST段升高心肌梗死(STEMI)。本研究旨在比较心肌梗死患者的结果,该患者接受纤维蛋白溶解治疗的成功结果,并在早期(第1组)与早期(第1组)(第2组)(第2组内)进行PCI(第2组)进行比较。方法研究比较PCI(无回流现象,接入位点出血,脑出血和心脏死亡期间主要不良心脏事件发生的发生。患者在PCI后6个月进行了不稳定的心绞痛,复发性心绞痛,非催眠,反复发作,重复血运重,心力衰竭和心脏死亡。结果组1(121名患者)平均年龄为59.93±10.43岁,与2组(144名患者)进行比较,平均年龄为62.84±10.22岁。除了年龄外,对于基线特征,2组没有显着差异。在第1组中没有回流现象较少?= 0.005,而接入位点出血和脑出血的发生率分别具有p值Δ= 0.001和0.049。在6个月的后续后续期间,在第2组中发生复发性心绞痛和反复性的非催眠剂,P值分别= 0.049和0.035,2组之间没有其他显着差异。结论在成功纤维蛋白溶解疗法后,在接受PCI的患者患者患者中,复发性缺血的经常性缺血的风险显着降低,但在这一次出血的风险增加。因此,建议患者在纤维蛋白溶解中接受成功的纤维蛋白溶解治疗以在3至12小时内进行非常早期的PCI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号